Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells

Journal of the National Cancer Institute

Volumn 92, Issue 17, 2000, Pages 1403-1413

  Chen, Xiaomei ^a   Danes, Christopher ^a   Lowe, Michael ^a   Herliczek, Thaddeus W ^a   Keyomarsi, Khandan ^a,b,c  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P21;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034612793     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.17.1403     Document Type: Article

References (69)

1. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
2. Endogenous hormones and breast cancer risk
3. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
4. The nuclear receptor superfamily: The second decade
5. Steroid hormone receptors: Many actors in search of a plot
6. The steroid and thyroid hormone receptor superfamily
7. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
8. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
9. Oestrogen receptor: A stable phenotype in breast cancer
10. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?
11. Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases
12. Estrogen receptor variants in clinical breast cancer
13. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
14. The value of estrogen and progesterone receptors in the treatment of breast cancer
15. Acquired estrogen independence and antiestrogen resistance in breast cancer
16. The role of the estrogen receptor in tumor progression
17. A potent specific pure antiestrogen with clinical potential
18. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
19. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
20. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
21. Cdk-independent activation of estrogen receptor by cyclin D1
22. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4
23. Inhibitors of mammalian G1 cyclin-dependent kinases
24. Cyclin dependent kinase inhibitors
25. CDK inhibitors: Positive and negative regulators of G1-phase progression
26. New functional activities for the p21 family of CDK inhibitors
27. The restriction point and control of cell proliferation
28. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
29. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent
30. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines
31. Up-regulated p21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis
32. Cyclin E, a redundant cyclin in breast cancer
33. A direct comparison of procedures for the detection of mycoplasma in tissue culture
34. Transcriptional regulation of estrogen receptor in breast carcinomas
35. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
36. Activation of transcriptionally inactive human estrogen receptors by cyclic adenosine 3',5'-monophosphate and ligands including antiestrogens
37. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression
38. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells
39. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
40. Deregulation of cyclin E in breast cancer
41. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines
42. Chemosensitivity testing of human lung cancer cell lines using the MTT assay
43. Cyclin E, a potential prognostic marker for breast cancer
44. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion
45. Arrest of the cell cycle by the tumor-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1
46. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
47. Auto-regulation of the estrogen receptor promoter
48. Involvement of the cell-cycle inhibitor CiP1/WAF1 and the E1A-associated p300 protein in terminal differentiation
49. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD
50. Induction of p21 (WAF-1/CIP1) during differentiation
51. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner
52. Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease
53. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line
54. p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
55. Thrombopoietin-induced differentiation of a human megakaryo-blastic leukemia cell line, CMK, involves transcriptional activation of p21 (WAF1/Cip1) by STAT5
56. Transcriptional activation of the CDk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
57. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human flbroblasts
58. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
59. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line
60. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells
61. Combined effect of Navelbine with medroxyprogesterone acetate against human breast carcinoma cells in vitro
62. p21 (WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours
63. Antagonistic action of novel 1 alpha,25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1 alpha,25-dihydroxyvitamin D3
64. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
65. Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells
66. p53-Independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation
67. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma
68. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma
69. Firefly luciferase gene: Structure and expression in mammalian cells